

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 27, 2024

Gritstone bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-38663
(Commission
File Number)

47-4859534
(IRS Employer
Identification No.)

5959 Horton Street, Suite 300
Emeryville, California
(Address of Principal Executive Offices)

94608
(Zip Code)

Registrant's Telephone Number, Including Area Code: 510 871-6100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	GRTSQ	N/A*

* On October 22, 2024, the registrant's common stock was suspended from trading on the Nasdaq Global Select Market. On October 22, 2024, the registrant's common stock began trading on the OTC Pink Marketplace maintained by the OTC Markets Group, Inc. under the symbol "GRTSQ."

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

As previously disclosed, on October 10, 2024, Gritstone bio, Inc. (the “Company”) filed a voluntary petition for relief (the “Chapter 11 Case”) under chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).

On November 27, 2024, the Company filed with the Bankruptcy Court its monthly operating report for the period beginning October 1, 2024 and ending October 31, 2024 (the “MOR”).

The information set forth in Item 7.01 of this Form 8-K will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD. The MOR is attached hereto as Exhibit 99.1. The MOR and other filings with the Bankruptcy Court related to the Chapter 11 Case may be available electronically at <https://veritaglobal.net/gritstone>. Documents and other information available on such website are not part of this Form 8-K and shall not be deemed incorporated by reference in this Form 8-K. The Company has included the website address in this Form 8-K as an inactive textual reference only.

The information contained in this Item 7.01 and in Exhibit 99.1 is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Cautionary Statement Regarding the MOR

The Company cautions investors and potential investors not to place undue reliance upon the information contained in the MOR, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The MOR is limited in scope, covers a limited time period and has been prepared solely for the purpose of complying with the reporting requirements of the Bankruptcy Court. The MOR is not audited or reviewed by independent accountants, was not prepared in accordance with generally accepted accounting principles in the United States, is in a format prescribed by applicable bankruptcy laws or rules, and is subject to future adjustment and reconciliation. The MOR also contains information for periods shorter and otherwise different from those contained in the Company’s reports required to be filed pursuant to the Exchange Act. There can be no assurance that, from the perspective of an investor or potential investor in the Company’s securities, the MOR is complete. Results set forth in the MOR should not be viewed as indicative of future results.

Cautionary Statements Regarding Trading in the Company’s Securities

The Company’s securityholders are cautioned that trading in the Company’s Common Stock during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company’s Common Stock may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its Common Stock.

Cautionary Statements Regarding Forward-Looking Statements

This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements contained in this Current Report on Form 8-K include, but are not limited to, statements regarding the process and potential outcomes of the Company’s Chapter 11 Case. These statements are based on management’s current expectations, and actual results and future events may differ materially due to risks and uncertainties, including, without limitation, risks inherent in the bankruptcy process, including the outcome of the Chapter 11 Case; the Company’s financial projections and cost estimates; the Company’s ability to raise additional funds during the Chapter 11 Case; the Company’s ability to sell any of its assets; the impact of the Chapter 11 Case on the listing of the Common Stock on the Nasdaq; and the effect of the Chapter 11 Case on the Company’s business prospects, financial results and business operations. These and other factors that may affect the Company’s future business prospects, results and operations are identified and described in more detail in the Company’s filings with the SEC, including the Company’s most recent Annual Report filed on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this Form 8-K. Except as required by applicable law, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Gritstone bio, Inc. Monthly Operating Report for the period ended October 31, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Gritstone bio, Inc.

Date: November 29, 2024

By: /s/ Andrew Allen
Andrew Allen
President and Chief Executive Officer

UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In Re. Gritstone Bio, Inc.

Case No. 24-12305

Debtor(s)

§
§
§
§

Jointly Administered

Monthly Operating Report

Chapter 11

Reporting Period Ended: 10/31/2024

Petition Date: 10/10/2024

Months Pending: 1

Industry Classification: 5 4 1 7

Reporting Method: Accrual Basis

Cash Basis

Debtor's Full-Time Employees (current):

0

Debtor's Full-Time Employees (as of date of order for relief):

0

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- Statement of cash receipts and disbursements
- Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
- Statement of operations (profit or loss statement)
- Accounts receivable aging
- Postpetition liabilities aging
- Statement of capital assets
- Schedule of payments to professionals
- Schedule of payments to insiders
- All bank statements and bank reconciliations for the reporting period
- Description of the assets sold or transferred and the terms of the sale or transfer

/s/ James O'Neill

Signature of Responsible Party

11/26/2024

Date

James O'Neill

Printed Name of Responsible Party

919 N. Market Street, 17th Flr., Wilmington, DE 19801
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore § 1320.4(a)(2) applies.



241230524112700000000002

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305

Part 1: Cash Receipts and Disbursements		Current Month	Cumulative
a.	Cash balance beginning of month	\$22,985,938	
b.	Total receipts (net of transfers between accounts)	\$22,373	\$22,373
c.	Total disbursements (net of transfers between accounts)	\$4,813,451	\$4,813,451
d.	Cash balance end of month (a+b-c)	\$18,194,860	
e.	Disbursements made by third party for the benefit of the estate	\$0	\$0
f.	Total disbursements for quarterly fee calculation (c+e)	\$4,813,451	\$4,813,451
Part 2: Asset and Liability Status (Not generally applicable to Individual Debtors. See Instructions.)		Current Month	
a.	Accounts receivable (total net of allowance)	\$33,964	
b.	Accounts receivable over 90 days outstanding (net of allowance)	\$33,964	
c.	Inventory (Book <input type="radio"/> Market <input type="radio"/> Other <input checked="" type="radio"/> (attach explanation))	\$0	
d.	Total current assets	\$21,419,157	
e.	Total assets	\$99,547,476	
f.	Postpetition payables (excluding taxes)	\$564,721	
g.	Postpetition payables past due (excluding taxes)	\$425,194	
h.	Postpetition taxes payable	\$4,129	
i.	Postpetition taxes past due	\$0	
j.	Total postpetition debt (f+h)	\$568,850	
k.	Prepetition secured debt	\$41,327,099	
l.	Prepetition priority debt	\$4,000	
m.	Prepetition unsecured debt	\$5,648,248	
n.	Total liabilities (debt) (j+k+l+m)	\$47,548,197	
o.	Ending equity/net worth (e-n)	\$51,999,279	
Part 3: Assets Sold or Transferred		Current Month	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$0
b.	Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	\$0	\$0
c.	Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$0
Part 4: Income Statement (Statement of Operations) (Not generally applicable to Individual Debtors. See Instructions.)		Current Month	Cumulative
a.	Gross income/sales (net of returns and allowances)	\$0	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	\$0	
c.	Gross profit (a-b)	\$0	
d.	Selling expenses	\$0	
e.	General and administrative expenses	\$6,430,890	
f.	Other expenses	\$3,655,827	
g.	Depreciation and/or amortization (not included in 4b)	\$506,149	
h.	Interest	\$497,356	
i.	Taxes (local, state, and federal)	\$103,442	
j.	Reorganization items	\$1,768,433	
k.	Profit (loss)	\$-12,962,096	\$-12,962,096

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305

Part 5: Professional Fees and Expenses

			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative	
a.	Debtor's professional fees & expenses (bankruptcy) <i>Aggregate Total</i>		\$0	\$0	\$0	\$0	
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i	Nothing to report		\$0	\$0	\$0	\$0
	ii			\$0	\$0	\$0	\$0
	iii						
	iv						
	v						
	vi						
	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
xxviii							
xxix							
xxx							
xxxi							
xxxii							
xxxiii							
xxxiv							
xxxv							
xxxvi							

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305

xxxvii					
xxxvii					
xxxix					
xl					
xli					
xlii					
xliii					
xliv					
xlv					
xlvi					
xlvii					
xlviii					
xlix					
l					
li					
lii					
liii					
liv					
lv					
lvi					
lvii					
lviii					
lix					
lx					
lxi					
lxii					
lxiii					
lxiv					
lxv					
lxvi					
lxvii					
lxviii					
lxix					
lxx					
lxxi					
lxxii					
lxxiii					
lxxiv					
lxxv					
lxxvi					
lxxvii					
lxxvii					

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305

lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						

			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
b.	Debtor's professional fees & expenses (nonbankruptcy) <i>Aggregate Total</i>		\$0	\$0	\$0	\$0
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i	Nothing to report		\$0	\$0	\$0	\$0
ii			\$0	\$0	\$0	\$0
iii						
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305

xv							
xvi							
xvii							
xviii							
xix							
xx							
xxi							
xxii							
xxiii							
xxiv							
xxv							
xxvi							
xxvii							
xxviii							
xxix							
xxx							
xxxi							
xxxii							
xxxiii							
xxxiv							
xxxv							
xxxvi							
xxxvii							
xxxviii							
xxxix							
xl							
xli							
xlii							
xliii							
xliv							
xlv							
xlvi							
xlvii							
xlviii							
xliv							
l							
li							
lii							
liii							
liv							
lv							
lvi							

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305

lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvii						
lxxxviii						
lxxxix						
xc						
xc i						
xc ii						
xc iii						
xc iv						
xc v						
xc vi						
xc vii						
xc viii						

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305

c.	xcix						
	c						
All professional fees and expenses (debtor & committees)				\$0	\$0	\$0	\$0

Part 6: Postpetition Taxes	Current Month	Cumulative
a. Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b. Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c. Postpetition employer payroll taxes accrued	\$0	\$0
d. Postpetition employer payroll taxes paid	\$86,834	\$86,834
e. Postpetition property taxes paid	\$0	\$0
f. Postpetition other taxes accrued (local, state, and federal)	\$36,000	\$36,000
g. Postpetition other taxes paid (local, state, and federal)	\$0	\$0

Part 7: Questionnaire - During this reporting period:

- a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No
- b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions) Yes No
- c. Were any payments made to or on behalf of insiders? Yes No
- d. Are you current on postpetition tax return filings? Yes No
- e. Are you current on postpetition estimated tax payments? Yes No
- f. Were all trust fund taxes remitted on a current basis? Yes No
- g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions) Yes No
- h. Were all payments made to or on behalf of professionals approved by the court? Yes No N/A
- i. Do you have:
 - Worker's compensation insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - Casualty/property insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - General liability insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
- j. Has a plan of reorganization been filed with the court? Yes No
- k. Has a disclosure statement been filed with the court? Yes No
- l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes No

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305

Part 8: Individual Chapter 11 Debtors (Only)

- | | |
|--|---|
| a. Gross income (receipts) from salary and wages | \$0 |
| b. Gross income (receipts) from self-employment | \$0 |
| c. Gross income from all other sources | \$0 |
| d. Total income in the reporting period (a+b+c) | \$0 |
| e. Payroll deductions | \$0 |
| f. Self-employment related expenses | \$0 |
| g. Living expenses | \$0 |
| h. All other expenses | \$0 |
| i. Total expenses in the reporting period (e+f+g+h) | \$0 |
| j. Difference between total income and total expenses (d-i) | \$0 |
| k. List the total amount of all postpetition debts that are past due | \$0 |
| l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)? | Yes <input type="radio"/> No <input checked="" type="radio"/> |
| m. If yes, have you made all Domestic Support Obligation payments? | Yes <input type="radio"/> No <input type="radio"/> N/A <input checked="" type="radio"/> |

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/co/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).


I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Celia Economides
 Signature of Responsible Party
Executive Vice President & Chief Financial Officer
 Title


Celia Economides
 Printed Name of Responsible Party
11/26/2024
 Date

Debtor's Name Gritstone Bio, Inc.


Case No. 24-12305




PageOnePartOne



PageOnePartTwo




PageTwoPartOne




PageTwoPartTwo

Debtor's Name Gritstone Bio, Inc.


Case No. 24-12305




Bankruptcy1to50



Bankruptcy51to100




NonBankruptcy1to50




NonBankruptcy51to100

Debtor's Name Gritstone Bio, Inc.

Case No. 24-12305



PageThree



PageFour

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:

GRITSTONE BIO, INC.,

Debtor.

Chapter 11

Case No. 24-12305

(Single Debtor)

MONTHLY OPERATING REPORT NOTES FOR OCTOBER 2024

On October 10, 2024 (the "Petition Date") the Debtor filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code with the Bankruptcy Court. The Debtor is operating their businesses and managing their property as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. The information provided herein, except as otherwise noted, is reported as of the Petition Date.

The following notes and statements of limitations and disclaimers should be referred to, and referenced in connection with, any review of this Monthly Operating Report (the "MOR").

1. **Introduction.** This MOR is unaudited and does not purport to represent financial statements prepared in accordance with accounting principles generally accepted in the United States ("GAAP"), and it is not intended to fully reconcile to the consolidated financial statements prepared by the Debtor. Information contained in this MOR has been derived from the Debtor's books and records, but does not reflect in all circumstances presentation for GAAP or SEC reporting purposes. Therefore, to comply with their obligations to provide MORs during this chapter 11 case, the Debtor have prepared this MOR using the best information presently available to them, which has been collected, maintained, and prepared in accordance with their historical accounting practices. Accordingly, this MOR is true and accurate to the best of the Debtor's knowledge, information, and belief, based on currently available data. The results of operations and financial position contained herein are not necessarily indicative of results that may be expected for any period other than the period covered by this MOR, and may not necessarily reflect the Debtor's future consolidated results of operations and financial position.
2. **Reservation of Rights.** This MOR is limited in scope, and unless otherwise noted, covers the period beginning on October 10, 2024, and ending October 31, 2024, and has been prepared solely for the purpose of complying with the monthly reporting requirements of the Debtor's chapter 11 case. The unaudited financial information has been derived from the Debtor's books and records. The information presented herein has not been subject to all procedures that typically would be applied to financial information in accordance with U.S. GAAP. Upon the application of such procedures,

the Debtors believe that the financial information could be subject to material change. The information furnished in this MOR includes normal recurring adjustments but does not include all of the adjustments that typically would be made for interim financial information presented in accordance with GAAP.

Given the complexity of the Debtor's business, inadvertent errors or omission may occur. Accordingly, the Debtor hereby reserve all of their rights to dispute the nature, validity, status, enforceability, or executory natures of any claim amount, agreement, representation, or other statement set forth in this MOR. Further, the Debtor reserves the right to amend or supplement this MOR, if necessary, but shall be under no obligation to do so.

3. **Basis of Presentation.** Although the Debtor generally prepare their financial statements on a consolidated basis, the MOR has been prepared on an entity-by- entity basis (excluding most intercompany eliminations). The financial information contained herein is unaudited, limited in scope, covers a limited time period, and has been prepared solely for the purpose of complying with the monthly reporting requirements for chapter 11 debtors issued by the UST.

The amounts reported in this MOR are as of October 31, 2024, the end of the Debtor's reporting period. This MOR covers the period beginning October 10, 2024 and ending October 31, 2024.

4. **Accounting Principles.** The Debtor maintain their financial records according to GAAP, however the MOR does not purport to represent financial statements prepared in accordance with GAAP, nor are they intended to be fully reconciled with the financial statements of the Debtor.

The Debtor generally prepare financial statements on a consolidated basis. To the extent that there are negative asset balances for an individual Debtor, such as accounts receivable and current assets, they may be due to certain intercompany elimination transactions or adjustments in each specific Debtor's books and records.

Not all tax entries for the period have been completed by the time this report was due to be filed. To the extent that there are negative liability balances for an individual Debtor, such as prepetition unsecured liabilities, they are expected to be resolved once all of the relevant tax entries and adjustments have been analyzed and completed.

5. **Currency.** Unless otherwise indicated, all amounts in the MOR are reflected in U.S. dollars.
6. **Consolidated Entity Accounts Payable and Disbursement Systems.** Cash is received and disbursed by the Debtors as described in the *Motion for Entry of Interim and Final Orders Authorizing the Debtors to (A) Continue Operating Cash Management System, (B) Honor Certain Prepetition Obligations Related Thereto, (C) Maintain Existing*

Business Forms, and (D) Granting Related Relief [Docket No. 10] (the “**Cash Management Motion**”) and the Debtor’s receipt and disbursement of cash is consistent with the Debtor’s historical cash management practices. Due to the consolidated cash management reporting system, certain cash payments may be paid out of a legal entity that is different than the legal entity at which the expenses were incurred. Also, certain cash receipts may be received in a different legal entity than the legal entity at which the accounts receivable is recorded. Disbursements attributed to each entity represent the entity on behalf of which payments were made, on a proportional allocated basis, from the consolidated cash management system.

7. **Supporting Documentation.** At the direction of the U.S. Trustee, the following schedules are attached to the MOR: (i) Statement of Cash Receipts and Disbursements; (ii) Balance Sheet; and (iii) Income Statement (profit or loss statement), (iv) Attestations relating to Bank Statements and Bank Reconciliations, (v) Description of assets sold or transferred, and (vi) Attestations relating to insurance policies.

Statement of Cash Receipts and Disbursements. Based on guidance received from the Office of the United States Trustee in connection with the completion of UST Form 11-MOR Part 1, Cash Receipts and Disbursements, reported cash receipts and disbursements should exclude intercompany and debtor-to-debtor transactions. As a result, for those debtors with net intercompany cash outflows or inflows during the reporting period, the ending cash balances reported on Form 11-MOR Part 1 may not match the ending cash balances per the Debtor’s bank statements or the Debtor’s books and records.

The Company maintains a separate restricted money market cash account, which, for the purposes of financial reporting is categorized as an “other” asset and not included in the cash balance. Accordingly, the MOR excludes this account and account balance from the beginning Petition Date balance as it relates to Part 1. For additional information on the money market bank account see Attachment 4b to the MOR.

Balance Sheet.

The amounts reported in this MOR reflects the Debtor’s financial statements for the period of October 1, 2024 through October 31, 2024. All asset and liability amounts disclosed herein, unless otherwise noted, are stated as of October 31, 2024. The MOR is limited in scope and has been prepared to report only certain amounts from the balance sheet.

Liabilities Subject to Compromise (“**LSTC**”): LSTC represent the Debtor’s estimate of prepetition claims to be resolved in connection with the chapter 11 case. As a result of the chapter 11 filing, the payment of prepetition liabilities are subject to compromise or other treatment under a plan of reorganization. The determination of how such liabilities will ultimately be settled or treated cannot be made until the Court approves a chapter 11 plan of reorganization. Accordingly, the ultimate amount of such liabilities is not determinable at this time. Prepetition liabilities that are subject to compromise under ASC 852 are preliminary and may be subject to, among other things, future adjustments

depending on Court actions, further developments with respect to disputed claims, determinations of the secured status of certain claims, the values of any collateral securing such claims, rejection of executory contracts, continued reconciliation or other events.

Values in the balance sheet attached hereto represent rounded numbers. Accordingly, subtotals may not agree to the summation of the rounded numbers presented.

Income Statement. The amounts reported in this MOR reflect the Debtors financial statements for the period of October 1, 2024 through October 31, 2024.

Part 1, Cash Receipts and Disbursements.

Amounts reported for cash receipts and disbursements exclude intercompany transfers among the Debtor.

Part 2: Asset and Liability Status.

Asset values are reported as of October 31, 2024. Prepetition liabilities reflect liabilities included in Liabilities Subject to Compromise on the Debtor's balance sheets, as well as other liabilities which may be uncompromised pursuant to the relief granted via the Debtor's various final first day orders. Prepetition and post-petition balances of uncompromised liabilities are reported to the best of the Debtor's knowledge.

Part 3: Assets Sold or Transferred.

There are no Assets Sold or Transferred during the month of October 2024.

Part 4: Income Statement.

Due to limitations inherent in its financial accounting system, it would be unduly burdensome and cost prohibitive for the Debtor to construct a separate income statement for the stub period between the Petition Date through October 31, 2024. Accordingly, the amounts reported in Part 4 include the full month of October 1, 2024 through October 31, 2024.

To supplement the information reported on the Income Statement, for the timeframe during the 10 days between October 1, 2024 through the Petition Date, the Debtor made disbursements totaling approximately \$6.9m. Material disbursements include \$2.138m payment to Woodruff Sawyer for insurance, \$1.0m to Genevant for Research & Development, \$846k to Kenmore Lessor for Rent, and \$282k to Emery Station West for Rent.

Part 5: Professional Fees and Expenses. For purposes of the MORs, bankruptcy professional fees are considered approved if the applicable monthly fee statement has been served and the objection deadline with regard to such monthly fee statement has expired prior to the end date of the MOR period.

The Debtor will pay retained professionals in accordance with the Order (I) Authorizing Employment and Payment of Professionals Utilized in the Ordinary Course of Business;

and (II) Granting Related Relief [Docket No. 192].

Part 7 Questionnaire.

7a. Were any payments made on prepetition debt?

Pursuant to certain orders of the Bankruptcy Court entered in the Debtor's chapter 11 cases (the "First Day Orders"), the Debtor was authorized (but not directed) to pay, among other things, certain prepetition claims of their employees, taxing authorities, insurers, and certain other prepetition creditors.

7c. Were any payments made to or on behalf of insiders?

With respect to insiders, all cash payments were made on account of ordinary course salaries and authorized travel and expense reimbursements. No non-cash transfers were made to insiders during this reporting period.

7d. Are you current on postpetition tax return filings?

In the ordinary course of business, the Debtor's tax filings may extend past the normal deadlines and become late in some instances. When this happens, the Debtor arrange to complete the filings and address any related fines and/or penalties. There are no tax filings that are currently late where the Debtor is not also in dialog with the related taxing authority to become compliant.

In re: Grystone Bio, Inc. Case Number: 24-12305
Reporting Period: 10/10/2024 - 10/31/2024

Attachment 1: 10/10/2024 - 10/31/2024 Schedule of Cash Receipts and Disbursements			
	Operating Account	Restricted Cash	Total Available Cash
\$ in actuals			
Receipts			
Third Party	22,373	4,535	22,373
OP Financing	-	-	-
Sale Proceeds / Restricted Cash	-	-	-
Intercompany	-	-	-
Total Receipts	22,373	4,535	22,373
Disbursements			
Third Party	4,813,451	-	4,813,451
Intercompany (including transfers to non-debtor entities)	-	-	-
Total Disbursements	4,813,451	-	4,813,451
Net Cash Flow	(4,791,078)	4,535	(4,791,078)
Cash Balance at Beginning of Month	22,885,930	5,348,063	22,885,930
Net Cash Flow	(4,791,078)	4,535	(4,791,078)
Cash Balance at End of Month	18,194,852	6,353,499	18,194,852

In re: Gritstone Bio, Inc.

Case Number: 24-12305
Reporting Period: 10/10/2024 - 10/31/2024

Attachment 2: Balance Sheet

\$ in actuals

Account Reference	Account #	Account	Sub-Account	Balance
ASSETS				
Total Current Assets				\$ 22,143,794.73
Total Fixed Assets				\$ 10,484,398.12
Total Other Assets				\$ 66,919,283.11
Total ASSETS				99,547,475.96
Liabilities & Equity				
Current Liabilities				
Total Accounts Payable				\$ 5,329,756.83
Total Credit Card				\$ 26,879.24
Total Other Current Liability				\$ 22,516,144.93
Total Long Term Liabilities				\$ 86,179,051.67
Total - 31100 - Stockholders' Equity	31100		Stockholders' Equity	\$ 24,824.93
Total - 32000 - Additional Paid-in Capital	32000		Additional Paid	\$ 748,930,423.47
Total - Equity		Equity		\$ 748,953,755.89
Retained Earnings				\$ (659,560,856.17)
Net Income				\$ (103,897,256.43)
Total Equity				\$ (14,504,356.71)
Total Liabilities & Equity				99,547,475.96

In re: Grifone Bio, Inc.

Case Number: 24-12305
Reporting Period: 10/1/2024 - 10/31/2024

Attachment 3: Statement of Operations			
\$ in actuals			
Account Reference	Account #	Account	Balance
Ordinary Income/Expense			
Total - 60100 - Personnel Related Expenses			\$3,350,897.22
Total - 61000 - Professional Fees & Services			\$730,136.38
Total - 62000 - Insurance			\$2,218,816.10
Total - 63000 - Administration			\$214,062.17
Total - 63100 - Taxes and Licenses			(\$5,098.29)
Total - 64000 - Depreciation			\$906,148.26
Total - 65000 - Facility			\$1,971,068.75
Total - 66000 - Travel & Entertainment			\$45,302.64
Total - 67000 - Clinical Trial			\$296,453.97
Total - 68000 - Lab Supplies and Consumables			\$176,633.40
Net Ordinary Income			(\$10,884,946.78)
Total - Other Income			\$13,466.44
Net Other Income			(\$17,151.55)
Net Income	Net Income		(\$11,198,732.33)

In re: Gritstone Bio, Inc.

Case Number:

24-12305

Reporting Period:

10/10/2024 - 10/31/2024

Attachment 4a: Attestation re Bank Reconciliations

The Debtor hereby submit this declaration regarding bank account reconciliations in lieu of providing copies of bank statements and copies of all account reconciliations.

The Debtor has, on a timely basis, performed all bank account reconciliation in the ordinary course of its business. Copies of bank account statements and reconciliations are available for inspection upon request by the United States Trustee's Office.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

/s/ Celia Economides

Signature of Authorized Individual

11/26/2024

Date

Celia Economides

Printed Name of Authorized Individual

Executive Vice President and Chief Financial Officer

Title of Authorized Individual

In re: Gritstone Bio, Inc.

Case Number: 24-12305
 Reporting Period: 10/10/2024 - 10/31/2024

Attachment 4b: Schedule of Bank Accounts

Debtor/Legal Entity	Case No.	Name of Institution	Type of Account	Last 4 Digits of Account No
Gritstone Bio, Inc.	24-12305	JP Morgan Chase Bank, N.A.	Operating Account	0182
Gritstone Bio, Inc.	24-12305	JP Morgan Chase Bank, N.A.	Savings Account	2959
Gritstone Bio, Inc.	24-12305	JP Morgan Chase Bank, N.A.	Line of Credit	0326
Gritstone Bio, Inc.	24-12305	US Bank	CAG Investment Account	3430
Gritstone Bio, Inc.	24-12305	US Bank	GS Investment Account	0710
Gritstone Bio, Inc.	24-12305	First-Citizens	First Citizens Debt Facility Account	3437

In re: Gritstone Bio, Inc.

Case Number:

24-12305

Reporting Period:

10/10/2024 - 10/31/2024

Attachment 5a: Attestation re Insurance Policies

The Debtor hereby submit this declaration regarding Insurance Policies.

The Debtor's Insurance Policies are paid current and in good standing. Attached hereto as Attachment 5b is a list of the Debtor's Insurance Policies with partially redacted policy numbers.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

/s/ Celia Economides

Signature of Authorized Individual

11/26/2024

Date

Celia Economides

Printed Name of Authorized Individual

Executive Vice President and Chief Financial Officer

Title of Authorized Individual

In re: Gritstone Bio, Inc.

Case Number: 24-12305
Reporting Period: 10/10/2024 - 10/31/2024

Attachment 5b: Insurance Policies

Type of Coverage	Insurer	Debtor	Policy Number (last four)	Period
24-25 Auto Policy (Chubb) - Revised	Federal Insurance Company	Gritstone Bio, Inc	7573	10/13/2024 - 10/13/2025
Issue Auto ID card(s)	Federal Insurance Company	Gritstone Bio, Inc	7573	10/13/2024 - 10/13/2025
24-25 Cyber Liability Binder (Coalition).pdf	Arch Specialty Insurance Company	Gritstone Bio, Inc	4092	10/13/2024 - 10/13/2025
23-24 D&O 1st Excess \$5M x \$5M Policy (Arch)	Arch Insurance Company	Gritstone Bio, Inc	1205	9/28/2023 - 3/28/2025
23-24 D&O 3rd Excess \$5M x \$15M Binder (Berkley).pdf	Berkley Insurance Company	Gritstone Bio, Inc	9121	9/28/2023 - 3/28/2025
23-24 D&O 2nd Excess \$5M x \$10M Binder (XL).pdf	XL Specialty Insurance Company	Gritstone Bio, Inc	5323	9/28/2023 - 3/28/2025
23-24 D&O 5th Side A \$5M xs \$25M Binder (Chubb).pdf	ACE American Insurance Company	Gritstone Bio, Inc	A005	9/28/2023 - 3/28/2025
23-24 D&O 4th Lead Side A \$5M xs \$20M Binder (AIG).pdf	National Union Fire Ins Co Pittsburgh, PA	Gritstone Bio, Inc	0672	9/28/2023 - 3/28/2025
Gritstone Bio Inc. \$5x\$30 Vantage Binder (v2).pdf	Vantage Risk Assurance Company	Gritstone Bio, Inc	6670	9/28/2023 - 3/28/2025
23-24 Primary D&O \$5M SIR RO endt (Startpoint)_Original.pdf	Lloyds of London	Gritstone Bio, Inc	1072	9/28/2023 - 3/28/2025
EPL Binder - Gritstone Bio 9.27.24 Arch.pdf	Arch Insurance Company	Gritstone Bio, Inc	1405	9/28/2023 - 3/28/2025
24-25 Fiduciary Binder (Chubb)	Federal Insurance Company	Gritstone Bio, Inc	2460	9/28/2023 - 3/28/2025
24-25 Fiduciary Liability Policy (Chubb)	Federal Insurance Company	Gritstone Bio, Inc	2460	9/28/2023 - 3/28/2025
24-25 P&C (Pkg. Prod. Umb) Binder (Chubb)	Federal Insurance Company	Gritstone Bio, Inc	5615	10/13/2024 - 10/13/2025
24-25 Pollution Liability Binder (Chubb).final	Illinois Union Insurance Company	Gritstone Bio, Inc	0005	10/13/2024 - 10/13/2025
24-25 P&C (Pkg. Prod. Umb) Binder (Chubb)	Federal Insurance Company	Gritstone Bio, Inc	7433	10/13/2024 - 10/13/2025
24-27 Business Travel Accident Policy (R&W)	Zurich American Insurance Company	Gritstone Bio, Inc	1843	10/13/2024 - 10/13/2025
24-25 Umbrella Policy (Chubb)	Federal Insurance Company	Gritstone Bio, Inc	3337	10/13/2024 - 10/13/2025
24-25 P&C (Pkg. Prod. Umb) Binder (Chubb)	Federal Insurance Company	Gritstone Bio, Inc	3337	10/13/2024 - 10/13/2025
24-25 Work Comp Policy (Travelers)	Travelers Prop Casualty Co of America	Gritstone Bio, Inc	416G	10/13/2024 - 10/13/2025